Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc.
Your view on PTGX
Overview
What the company does, where it operates, and who runs it.
About Protagonist Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Dinesh V. Patel
- Headquarters
- 7707 Gateway Boulevard, Newark, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Dinesh V. Patel
- Headquarters
- 7707 Gateway Boulevard, Newark, CA, US
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases.
It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications.
The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Protagonist Therapeutics, Inc., and the rating behind it. PTGX last traded at $148.18, 121.6× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Protagonist Therapeutics, Inc.. Starting points for Protagonist Therapeutics, Inc.: P/E 121.6, EPS $1.26, beta 1.79 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Protagonist Therapeutics, Inc.. Protagonist Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Protagonist Therapeutics, Inc.. Trailing twelve-month EPS for Protagonist Therapeutics, Inc. stands at $1.26. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Protagonist Therapeutics, Inc.. Protagonist Therapeutics, Inc. has reported as a listed company since 2016. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Protagonist Therapeutics, Inc. valued side by side against its closest peers. Protagonist Therapeutics, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Protagonist Therapeutics, Inc., and how their positions are changing. At a $9.53B market value, institutional positions materially move Protagonist Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Protagonist Therapeutics, Inc. executives and directors. Shares of Protagonist Therapeutics, Inc. have traded between $33.70 and $93.25 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Protagonist Therapeutics, Inc.. Protagonist Therapeutics, Inc. is a $9.53B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Protagonist Therapeutics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Protagonist Therapeutics, Inc.. Coverage tracks Protagonist Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.